Ірландія - англійська - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - secobarbital sodium - capsule - 100 milligram

Європейський Союз - англійська - EMA (European Medicines Agency)

mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

Сінгапур - англійська - HSA (Health Sciences Authority)

merck pte. ltd. - somatostatin acetate eqv somatostatin - injection, powder, for solution - 3 mg/ampoule - somatostatin acetate eqv somatostatin 3 mg/ampoule

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - amobarbital secobarbital sodium - capsule - 100 milligram

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - amobarbital secobarbital sodium - capsule - 200 milligram

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

erythromycin lactobionate -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - erythromycin lactobionate, quantity: 1515 mg (equivalent: erythromycin, qty 1 g) - injection, powder for - excipient ingredients: - indications as at 1 november 2002: oral erythromycin is not considered to be the antibiotic of choice in severely ill patients. erythrocin-i.v. (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time. upper respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). lower respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae). respiratory tract infections due to mycoplasma pneumoniae. skin and skin structure infections caused by streptococcus pyogenes and staphylococcus aureus (resistant staphylococci may emerge during treatment). diphtheria - as an adjunct to diphtheria antitoxin in infections due to corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers. acute pelvic inflammatory disease caused by neisseria gonorrhoeae: erythrocin-i.v. (sterile erythromycin lactobionate) followed by erythromycin stearate, base or ethyl succinate orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by n. gonorrhoeae in female patients with a history of sensitivity to penicillin. before treatment of gonorrhoea, patients who are suspected of also having syphilis should have microscopic examination for t. pallidum (by immunofluorescence or darkfield) before receiving erythromycin and monthly serologic tests for a minimum of 4 months thereafter. legionnaires' disease caused by legionella pneumophila. although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease.

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

viatris limited - erythromycin ethylsuccinate 482mg equivalent to erythromycin 400 mg (plus 3% overage) - film coated tablet - 400 mg - active: erythromycin ethylsuccinate 482mg equivalent to erythromycin 400 mg (plus 3% overage) excipient: calcium hydrogen phosphate magnesium stearate maize starch opadry pink oy-b-34901 povidone purified talc purified water sodium starch glycolate sorbic acid - streptococcus pyogenes (group a beta-haemolytic streptococcus): upper and lower respiratory tract, skin and soft tissue infections of mild to moderate severity. when oral medication is preferred for treatment of streptococcal pharyngitis and in long term prophylaxis of rheumatic fever, erythromycin is an alternate drug of choice. when oral medication is given, the importance of strict adherence by the patient to the prescribed dosage regimen must be stressed. a therapeutic dose should be administered for at least 10 days. prevention of initial attacks of rheumatic fever: penicillin is considered to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of group a beta-haemolytic streptococcal infections of the upper respiratory tract e.g. tonsillitis or pharyngitis). erythromycin is indicated for the treatment of penicillin-allergic patients. the therapeutic dose should be administered for 10 days. prevention of recurrent attacks of rheumatic fever: penicillin or sulphonamides are considered to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. in patients who are allergic to penicillin and sulphonamides, oral erythromycin is recommended in the long term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever).

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

viatris limited - erythromycin ethylsuccinate 46.8 mg/ml equivalent to erythromycin 40 mg/ml (does not include 10% overage) - granules for oral suspension - 200 mg/5ml - active: erythromycin ethylsuccinate 46.8 mg/ml equivalent to erythromycin 40 mg/ml (does not include 10% overage) excipient: aspartame cherry flavour 163837 colloidal silicon dioxide erythrosine propylene glycol alginate sodium benzoate sodium citrate dihydrate sorbitol - streptococcus pyogenes (group a beta-haemolytic streptococcus): upper and lower respiratory tract, skin and soft tissue infections of mild to moderate severity. when oral medication is preferred for treatment of streptococcal pharyngitis and in long term prophylaxis of rheumatic fever, erythromycin is an alternate drug of choice. when oral medication is given, the importance of strict adherence by the patient to the prescribed dosage regimen must be stressed. a therapeutic dose should be administered for at least 10 days. prevention of initial attacks of rheumatic fever: penicillin is considered to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of group a beta-haemolytic streptococcal infections of the upper respiratory tract e.g. tonsillitis or pharyngitis). erythromycin is indicated for the treatment of penicillin-allergic patients. the therapeutic dose should be administered for 10 days. prevention of recurrent attacks of rheumatic fever: penicillin or sulphonamides are considered to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. in patients who are allergic to penicillin and sulphonamides, oral erythromycin is recommended in the long term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever).

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

viatris limited - erythromycin ethylsuccinate 93.6 mg/ml equivalent to erythromycin 80 mg/ml (does not include 10% overage) - granules for oral suspension - 400 mg/5ml - active: erythromycin ethylsuccinate 93.6 mg/ml equivalent to erythromycin 80 mg/ml (does not include 10% overage) excipient: aspartame cherry flavour 163837 colloidal silicon dioxide erythrosine propylene glycol alginate sodium benzoate sodium citrate dihydrate sorbitol - streptococcus pyogenes (group a beta-haemolytic streptococcus): upper and lower respiratory tract, skin and soft tissue infections of mild to moderate severity. when oral medication is preferred for treatment of streptococcal pharyngitis and in long term prophylaxis of rheumatic fever, erythromycin is an alternate drug of choice. when oral medication is given, the importance of strict adherence by the patient to the prescribed dosage regimen must be stressed. a therapeutic dose should be administered for at least 10 days. prevention of initial attacks of rheumatic fever: penicillin is considered to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of group a beta-haemolytic streptococcal infections of the upper respiratory tract e.g. tonsillitis or pharyngitis). erythromycin is indicated for the treatment of penicillin-allergic patients. the therapeutic dose should be administered for 10 days. prevention of recurrent attacks of rheumatic fever: penicillin or sulphonamides are considered to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. in patients who are allergic to penicillin and sulphonamides, oral erythromycin is recommended in the long term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever).